de Mello Diego Claro, Menezes Joice Moraes, de Oliveira Antonio Tarelo Freitas, Cristovão Marcella Maringolo, Kimura Edna Teruko, Fuziwara Cesar Seigi
Universidade de São Paulo Instituto de Ciências Biomédicas Departamento de Biologia Celular e do Desenvolvimento São PauloSP Brasil Departamento de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil.
Arch Endocrinol Metab. 2024 Nov 6;68(Spec Issue):e240073. doi: 10.20945/2359-4292-2024-0073. eCollection 2024.
Modulating the expression of a coding or noncoding gene is a key tool in scientific research. This strategy has evolved methodologically due to advances in cloning approaches, modeling/algorithms in short hairpin RNA (shRNA) design for knockdown efficiency, and biochemical modifications in RNA synthesis, among other developments. Overall, these modifications have improved the ways to either reduce or induce the expression of a given gene with efficiency and facility for implementation in the lab. Allied with that, the existence of various human cell line models for cancer covering different histotypes and biological behaviors, especially for thyroid cancer, has helped improve the understanding of cancer biology. In this review, we cover the most frequently used current techniques for gene modulation in the thyroid cancer field, such as RNA interference (RNAi), short hairpin RNA (shRNA), and gene editing with CRISPR/Cas9 for inhibiting a target gene, and strategies to overexpress a gene, such as plasmid cloning and CRISPRa. Exploring the possibilities for gene modulation allows the improvement of the scientific quality of the studies and the integration of clinicians and basic scientists, leading to better development of translational research.
Arch Endocrinol Metab. 2024-11-6
Methods Mol Biol. 2020
Methods Mol Biol. 2020
Hum Gene Ther. 2018-11-20
Adv Exp Med Biol. 2023
Methods Enzymol. 2017
Int J Mol Sci. 2016-2-26
JAMA. 2024-2-6
Nat Rev Endocrinol. 2024-2
Nat Rev Cancer. 2023-9
Cancer Discov. 2023-8-4
J Clin Invest. 2023-6-1